Drug Profile
ARX 788
Alternative Names: Antibody-drug conjugate - Ambrx/Zhejiang Medicine; ARX-788; JNJ-0683; NCB-001Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx
- Developer Ambrx; NovoCodex Biopharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Small molecules
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III HER2 positive breast cancer
- Phase I Gastric cancer
- Suspended Breast cancer; Solid tumours
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 25 Jan 2024 Ambryx plans a phase II trial for Breast cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in the US (IV) (NCT06224673)
- 05 Dec 2023 Efficacy and adverse events data from a phase I trial in Solid tumours cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)